Amylyx Pharmaceuticals Files 8-K
Ticker: AMLX · Form: 8-K · Filed: Aug 27, 2025 · CIK: 1658551
Sentiment: neutral
Topics: 8-K, regulatory-filing
TL;DR
Amylyx filed an 8-K, something happened.
AI Summary
Amylyx Pharmaceuticals, Inc. filed an 8-K on August 27, 2025, to report other events. The filing does not contain specific details about the nature of these events, dollar amounts, or definitive dates beyond the filing date itself.
Why It Matters
This filing indicates a material event has occurred for Amylyx Pharmaceuticals, requiring disclosure to investors, though the specifics are not yet detailed.
Risk Assessment
Risk Level: medium — The filing is an 8-K, which typically signifies a material event, but the lack of specific details in this report creates uncertainty.
Key Numbers
- 001-41199 — Commission File Number (Identifier for the company's SEC filings)
- 46-4600503 — IRS Employer Identification No. (Tax identification number for the company)
Key Players & Entities
- Amylyx Pharmaceuticals, Inc. (company) — Registrant
- August 27, 2025 (date) — Date of earliest event reported
- 43 Thorndike St. (location) — Principal Executive Offices
- Cambridge, MA (location) — Principal Executive Offices
- 02141 (location) — Zip Code
FAQ
What specific event is Amylyx Pharmaceuticals reporting in this 8-K filing?
The filing is categorized under 'Other Events' and does not provide specific details about the event itself within the provided text.
When was the earliest event reported in this filing?
The earliest event reported is dated August 27, 2025.
What is the principal executive office address for Amylyx Pharmaceuticals?
The principal executive offices are located at 43 Thorndike St., Cambridge, MA 02141.
What is the Commission File Number for Amylyx Pharmaceuticals?
The Commission File Number for Amylyx Pharmaceuticals is 001-41199.
Under which section of the Securities Exchange Act is this Form 8-K filed?
This Form 8-K is filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
Filing Stats: 439 words · 2 min read · ~1 pages · Grade level 11.8 · Accepted 2025-08-27 07:05:43
Key Financial Figures
- $0.0001 — ange on which registered Common Stock, $0.0001 par value per share AMLX Nasdaq Glo
Filing Documents
- d23231d8k.htm (8-K) — 22KB
- 0001193125-25-189109.txt ( ) — 129KB
- amlx-20250827.xsd (EX-101.SCH) — 3KB
- amlx-20250827_lab.xml (EX-101.LAB) — 17KB
- amlx-20250827_pre.xml (EX-101.PRE) — 11KB
- d23231d8k_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. AMYLYX PHARMACEUTICALS, INC. Date: August 27, 2025 By: /s/ James M. Frates James M. Frates Chief Financial Officer